Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

However, sell-offs present great opportunities to buy stocks with significant upside potential. Further, CRISPR Therapeutics ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Democratic Kansas Gov. Laura Kelly condemned Republican overreach in health care as she announced Wednesday evening a list of ...

Food additive mixtures commonly found in diet drinks, soups, dairy desserts and sauces may slightly increase a person's risk ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

The AI models occasionally altered decisions based on patients’ personal characteristics, affecting priority for care and ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

A new study focused on transcription-replication conflicts, which occur when mechanisms responsible for gene expression and genome duplication collide.